In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no ...

Autologous mononuclear cells showed substantial activity in patients with advanced heart failure — and even though the study ...

The following is a summary of "A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study," ...

The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global ...

Induced pluripotent stem cells are being tested to treat blindness, paralysis, Parkinson’s disease and more. Approvals might ...

Explore the advancements in stem cell therapy for neurodegenerative diseases. Discover market size, trends, and growth projections for 2035 with a focus on treatment innovations.

Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM).

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after ...

Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed ...